Startup Vicebio banks $100M in bid to make ‘cost-effective’ vaccines

Startup Vicebio banks $100M in bid to make ‘cost-effective’ vaccines

Source: 
BioPharma Dive
snippet: 

The company’s technology, which enables it to skip an expensive manufacturing step, could lead to vaccines that are easier to produce, said CEO Emmanuel Hanon.